3-Hydroxyphencyclidine (3-HPC), a breakdown product of phencyclidine (PCP), is growing attracting clinical focus due to sparse evidence suggesting different pharmacological properties. Preliminary studies suggest that 3-HPC may exhibit distinct impacts on the brain structure, arguably influencing to some of the unanticipated manifestations associat